3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
8
Recruiting
4
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Head & Neck
2
Endocrine
2
Dermatologic
2
CNS
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Neoplasm Metastasis
1
Interventions
pembrolizumab
17
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
8
Paclitaxel
7
Biopsy
7
Nivolumab
6
atezolizumab
5
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Practice Guidelines as Topic
4
Pemetrexed
4
Oxaliplatin
4
Cyclophosphamide
4
Carboplatin
4
osimertinib
3
niraparib
3
durvalumab
3
cemiplimab
3
avelumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Interviews as Topic
3
Fluorouracil
3
trastuzumab deruxtecan
2
trametinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Vemurafenib
×
Tumor-Agnostic
×
Clear all
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT02304809
2025-08-01
AcSé
UNICANCER
Phase 2
Active not recruiting
216 enrolled